INS and type 2 diabetes mellitus: Preclinical studies showed that imeglimin improved hyperglycaemia and enhanced glucose‐stimulated insulin secretion (GSIS) using multiple rodent models of T2D (isolated islets and intact animals), including models characterized by a primary defect in β‐cell mass and function.6, 8, 9, 10, 11